drugset / Trial / NCT02963064
JSP191 Antibody Targeting Conditioning in SCID Patients
NaSingle-groupOpen-labelTreatment
Summary
A Phase 1/2 study to evaluate the safety, tolerability, and efficacy of an antibody conditioning regimen, known as JSP191, in patients with Severe Combined Immune Deficiency undergoing blood stem cell transplantation
Timeline
- Start
- 2017-03-20
- Primary completion
- 2025-07-07
- Completion
- 2025-07-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Briquilimab | Monoclonal antibody | — | Intravenous |